Details of the Drug-Related molecule(s) Activity Atlas
General Information of Drug (ID: DMYLT67)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
|
|||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Cross-matching ID | ||||||
Molecule-level Activity Landscape of This Drug
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Experimental Drug Sensitivity Data Across Cancer Cell Lines
|
|
||||||||||||||||
|
||||||||||||||||
Cytotoxic Activity Landscape of This Drug
|
||||||||||||||||
